Neuronetics, Inc.
STIMHealthcareNASDAQMedical Devices · Last scanned Oct 23, 2026
Scan Results
Daily timeframeNeuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The $158.5M market capitalization puts STIM squarely in micro-cap range for its industry. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Market Cap
$158.5M
Beta
1.20
P/E (TTM)
—
P/E (Fwd)
-6.12
EPS (TTM)
$-0.45
EPS (Fwd)
$-0.34
ROE
-116.1%
ROA
-10.5%
Cash
$19.2M
Total Debt
$86.5M
Free CF
$345,625
52W Change
-29.7%
Annual Financials
Cash vs Debt
Where STIM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, STIM finished 1.04% below its 150-day moving average ($1.93) and 3.24% above its 200-day moving average ($1.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STIM overbought or oversold?
At the October 20, 2026 close, STIM's RSI(14) was 19.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Neuronetics, Inc. carries $86.5M in total debt against $19.2M in cash reserves — debt is roughly 4.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $346K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -116.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $65.2M (2022) to $149.2M (2025), reflecting a 129% increase over the period.
As with any equity investment, STIM carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Neuronetics, Inc. and its sector.